BioCentury | Apr 18, 2018
Distillery Therapeutics

Cancer

...pan-CDC25 inhibitor decreased viability compared with vehicle. In a xenograft mouse model of TNBC, the pan-CDC25...
...decreased tumor volume compared with the pan-CDC25 inhibitor alone. Next steps include identifying and testing CDC25...
...De Leon University of Toronto Cell division cycle 25 homolog A (CDC25A) Cell division cycle 25B (CDC25B) Cell division cycle 25C (CDC25C) (CDC25) Phosphoinositide...
BioCentury | Nov 13, 2014
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms CD8+ T cells that express phosphopeptide-targeted T cell receptor (TCR) to treat cancer Mouse studies suggest CD8+ T cells expressing TCRs that engage with phosphopeptide...
BioCentury | Aug 29, 2013
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma Cyclic adenosine monophosphate (cAMP); cell division cycle 25B (CDC25B); melanocortin 1 receptor (MC1R) Cell culture studies suggest targeting the MC1R-cAMP-CDC25B...
BioCentury | Feb 9, 2012
Cover Story

Bringing on the BRAF

...PKBA ; AKT; AKT1 ) pathway and the Ras-Raf-MEK-MAPK (ERK) pathway. Cell division cycle 25C ( CDC25C ; CDC25...
...and deactivates EGFR ( I ). The group postulates that BRAF inhibition leads to decreased CDC25C...
BioCentury | Sep 14, 2009
Company News

Debiopharm S.A., Ipsen deal

...worldwide license to Debio 0931 (formerly IRC-083864) to treat cancer. The cell division cycle 25C ( CDC25C , CDC25...
BioCentury | Oct 16, 2006
Tools & Techniques

Understanding the translation

The idea of tumor-specific antigens is hardly new, but much of the work has focused on the expression of a mutant gene that produces a mutant protein, which then serves as an epitope. Another approach...
BioCentury | Jan 16, 2006
Strategy

Ipsen's pipeline

...BIM 46187 Compound acting on cellular signals by receptors attached to Protein G Cancer Preclin cdc25...
BioCentury | Feb 19, 2002
Company News

National Institute of Health other research news

...inhibiting Cdc2/cyclin B kinase. BRCA1 expression inhibited cyclin B kinase by localizing the regulatory protein Cdc25...
BioCentury | Dec 18, 2000
Strategy

Partners of BASF and Abbott

Partners of BASF and Abbott Company Deal summary Alza (AZA) Marketing of Oros hydromorphone pain product BioSignal High-throughput screening Cambridge Antibody (LSE:CAT) Antibodies for autoimmune/inflammation Evotec (NMarkt:EVT) Compound screening Genzyme (GENZ) Co-marketing of GENZ's Thyrogen...
BioCentury | Dec 15, 1997
Clinical News

Mitotix regulatory update

Five U.S. Patents related to cell cycle regulation issued either to the company or to entities from which the company has exclusive licenses. No. 5,672,508, issued to Mitotix, claims nucleic acids that encode peptide fusions...
Items per page:
1 - 10 of 13